Can zapping all spots of prostate cancer delay progression? PLATON trial aims to find out
NCT ID NCT03784755
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409 men with up to 5 metastases are being randomly assigned to receive either standard care alone or standard care plus ablative therapy. The main goal is to see if this approach delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Algoma District Cancer Program
Sault Ste. Marie, Ontario, P6B 0A8, Canada
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
BCCA - Victoria
Victoria, British Columbia, V8R 6V5, Canada
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CIUSSS de l'Est-de-I'lle-de-Montreal
Montreal, Quebec, H1T 2M4, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Health Sciences North
Greater Sudbury, Ontario, P3E 5J1, Canada
-
Hotel-Dieu de Quebec
Québec, Quebec, G1R 2J6, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
-
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4, Canada
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Trillium Health Partners - Credit Valley Hospital
Mississauga, Ontario, L5M 2N1, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ablative radiation therapy (SBRT) or surgery
What this could lead to
If successful, this could show that treating all visible cancer spots with radiation or surgery, alongside standard hormone therapy, delays cancer progression better than standard therapy alone.
What could go wrong
This is an active but not recruiting phase 3 trial, so results are not yet available. Adding local therapy may not improve outcomes and could cause side effects from extra radiation or surgery.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.